enrichment design
Recently Published Documents


TOTAL DOCUMENTS

43
(FIVE YEARS 4)

H-INDEX

7
(FIVE YEARS 0)

2021 ◽  
Vol 49 (5) ◽  
Author(s):  
Zhantao Lin ◽  
Nancy Flournoy ◽  
William F. Rosenberger
Keyword(s):  

2021 ◽  
Vol 100 ◽  
pp. 106216
Author(s):  
Ruitao Lin ◽  
Zhao Yang ◽  
Ying Yuan ◽  
Guosheng Yin

Author(s):  
Fang Xia ◽  
Stephen L. George ◽  
Jing Ning ◽  
Liang Li ◽  
Xuelin Huang

2019 ◽  
Vol 30 (4) ◽  
pp. 623-638 ◽  
Author(s):  
Yanxun Xu ◽  
Florica Constantine ◽  
Yuan Yuan ◽  
Yili L. Pritchett

2019 ◽  
Vol 9 (4-s) ◽  
pp. 803-805
Author(s):  
Rada Santosh Kumar ◽  
K. Shambhavi

Identification of a human subject into a study for a clinical trial involves screening and placebo run in periods. In some cases additional screening process is required as some therapeutic agents will be effective in patients with some disorders as they show changes in response. Hence, an additional screening process called Enrichment design is employed in the clinical trials which includes active treatments as it helps in easy identification of patients in whom test agents are found to be beneficial during early phase of trial. They also helps in identification of patients with better therapeutic response. Thus, this additional screening process restricts the target population into a very small selective group during the clinical trial making the trial process easier and effective.


2019 ◽  
Vol 30 (1) ◽  
pp. 18-30
Author(s):  
A. Adam Ding ◽  
Samuel S. Wu ◽  
Natalie E. Dean ◽  
Rachel S. Zahigian

Sign in / Sign up

Export Citation Format

Share Document